Found 4,433 articles
Genezen announced licensing of the Cytegrity™ proprietary stable production system from biotechnology leader CSL.
A week after Britain’s debut of the four-week Kwikpen, a European Medicines Agency panel is slated to review Eli Lilly’s multi-dose, pre-filled pen injector for diabetes drug Mounjaro.
Royal Philips, a global leader in health technology, has relentlessly focused on further improving its Environmental, Social, and Governance performance in 2023.
This announcement is a summary of Bioretec Ltd's financial statements bulletin for January-December 2023.
Grifols announced that Biotest’s positive topline results from AdFIrst, its phase 3 clinical trial of its fibrinogen concentrate, BT524, advance this potential treatment for acquired fibrinogen deficiency, an underserved growth market.
eGenesis and PorMedTec Announce Successful Production of Genetically Engineered Porcine Donors in Japan
eGenesis and PorMedTec have successfully produced genetically engineered porcine donors in Japan for use in transplantation.
PharmaTher Holdings Ltd. provides an update of its Priority Original Abbreviated New Drug Application (“ANDA”) for Ketamine that was accepted by the U.S. Food and Drug Administration (the “FDA”) and assigned a Generic Drug User Fee Amendments of 2022 (“GDUFA”) goal date of April 29, 2024.
The European Medicines Agency is looking into how Novo Holdings’ recently announced $16.5 billion acquisition of contract manufacturer Catalent might affect the availability of drugs.
With manufacturing issues persisting, last year’s shortages of medicines, including chemotherapies, weight-loss drugs and antibiotics, will continue into 2024.
Trinity Biotech Plc. has applied for a Proprietary Laboratory Analyses (PLA) code for its Early Sjögrens Syndrome Test Panel, to allow for an optimised market access strategy to deliver broader patient access and improved profitability.
Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”) announced today that it has concluded its interaction with the U.S. Food and Drug Administration (“FDA”) on optimizing the development plan for its stroke program which aims to evaluate the effects of cranial-nerve non-invasive neuromodulation (“CN-NINM”) delivered using PoNS Therapy® on gait and dynamic balance in chronic stroke survivors.
Helius Booth and Special Event at APTA Combined Sections Meeting Will Highlight Physical Therapists’ Ability to Customize PoNS Therapy® to Improve Gait in People with MS
Helius Medical Technologies, Inc. is expanding its presence at the 2024 American Physical Therapy Association Combined Sections Meeting, held February 15 through February 17 at the Boston Convention and Exposition Center: In addition to exhibiting its innovative Portable Neuromodulation Stimulator at booth 7074, the company also is hosting an after-hours event on February 16.
Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its once-daily vanzacaftor/tezacaftor/deutivacaftor (the “vanza triple”) program, the most comprehensive Phase 3 pivotal program ever conducted by Vertex for the treatment of cystic fibrosis (CF), a progressive, multi-organ disease caused by dysfunction of the CFTR protein.
The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.
The persistent shortage of genuine glucagon-like peptide 1 receptor agonist products has led to an increase in fake versions, the World Health Organization warned on Monday.
BD, Techcyte Announce Strategic Collaboration to Offer AI-Based Digital Cervical Cytology System for Pap Testing
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Techcyte, a world leader in artificial intelligence (AI) digital diagnostics, today announced a strategic collaboration agreement to offer an AI-based algorithm that guides cytologists and pathologists to efficiently and effectively identify evidence of cervical cancer and precancer using whole-slide imaging.
Biotricity Expands Development of its Cardiac AI Cloud Platform with Data Ecosystem of over 360 billion Heartbeats
Biotricity Inc., a leading medical diagnostic and consumer healthcare technology company, announced the expanding development of its future Cardiac AI Cloud platform.
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today highlighted key updates from its oral presentation at the 5th International Conference on Base Editing, Prime Editing & Related Enzymes (Deaminet 2024) in San Diego, California.
Merck Animal Health's Fourth Veterinary Wellbeing Study Indicates Progress in Addressing Mental Health Challenges Among Veterinary Teams
Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA, released findings of its comprehensive Veterinary Wellbeing Study conducted in collaboration with the American Veterinary Medical Association.
Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital
Helius Medical Technologies, Inc. today announced the expansion of the registrational program with the addition of Brooks Rehabilitation Hospital (“Brooks Rehabilitation”).